AR102417A1 - Anticuerpos biespecíficos anti-tnf- / anti-il-23 - Google Patents
Anticuerpos biespecíficos anti-tnf- / anti-il-23Info
- Publication number
- AR102417A1 AR102417A1 ARP150103442A ARP150103442A AR102417A1 AR 102417 A1 AR102417 A1 AR 102417A1 AR P150103442 A ARP150103442 A AR P150103442A AR P150103442 A ARP150103442 A AR P150103442A AR 102417 A1 AR102417 A1 AR 102417A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- scfv
- hcvr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Los anticuerpos biespecíficos son útiles para el tratamiento de varias enfermedades autoinmunitarias que incluyen la enfermedad inflamatoria intestinal, tal como la enfermedad de Crohn y la colitis ulcerosa, espondiloartritis axial, artritis reumatoide y artritis psoriásica. Reivindicación 1: Un anticuerpo biespecífico que comprende un anticuerpo de inmunoglobulina (IgG) que se une al factor de necrosis tumoral a (TNFa) conjugado con dos fragmentos variables de cadena simple (scFv) que se unen a la subunidad p19 de IL-23 (IL23p19) donde, a) dicha IgG comprende dos cadenas pesadas (HC) y dos cadenas ligeras (LC), cada HC comprende una región variable de cadena pesada (HCVR1) que comprende CDR de cadena pesada (HCDR) 1 - 3 y cada LC comprende una región variable de cadena ligera (LCVR1) que comprende CDR de cadena ligera (LCDR) 1 - 3, donde la secuencia de aminoácidos de HCDR1 es la SEQ ID Nº 9, la secuencia de aminoácidos de HCDR2 es la SEQ ID Nº 10, la secuencia de aminoácidos de HCDR3 es la SEQ ID Nº 11, la secuencia de aminoácidos de LCDR1 es la SEQ ID Nº 15, la secuencia de aminoácidos de LCDR2 es la SEQ ID Nº 16, y la secuencia de aminoácidos de LCDR3 es la SEQ ID Nº 17; y b) cada scFv comprende una región variable de cadena pesada (HCVR2) y una región variable de cadena ligera (LCVR2), la HCVR2 comprende las HCDR 4 - 6 y la LCVR2 comprende las LCDR 4 - 6, donde la secuencia de aminoácidos de HCDR4 es la SEQ ID Nº 12, la secuencia de aminoácidos de HCDR5 es la SEQ ID Nº 13, la secuencia de aminoácidos de HCDR6 es la SEQ ID Nº 14, la secuencia de aminoácidos de LCDR4 es la SEQ ID Nº 18, la secuencia de aminoácidos de LCDR5 es la SEQ ID Nº 19, y la secuencia de aminoácidos de LCDR6 es la SEQ ID Nº 20, donde cada scFv está independientemente conjugado con dicho anticuerpo de IgG a través de un enlazador polipeptídico (L1) unido de forma covalente al extremo C de cada HC de IgG y el extremo N de la HCVR2 de cada scFv, y la HCVR2 de cada scFv está unida de forma covalente a la LCVR2 del mismo scFv a través de un segundo enlazador polipeptídico (L2) unido de forma covalente al extremo C de la HCVR2 y el extremo N de la LCVR2 del mismo scFv. Reivindicación 4: Una molécula de ADN que comprende una secuencia de polinucleótidos que codifica una cadena de polipéptidos que comprende una HC, un scFv, un enlazador polipeptídico y un segundo enlazador polipeptídico del anticuerpo biespecífico de cualquiera de las reivindicaciones 1 - 3. Reivindicación 10: Una célula de mamífero que comprende la molécula de ADN de cualquiera de las reivindicaciones 4 - 9.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075571P | 2014-11-05 | 2014-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102417A1 true AR102417A1 (es) | 2017-03-01 |
Family
ID=54477413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103442A AR102417A1 (es) | 2014-11-05 | 2015-10-23 | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9718884B2 (es) |
| EP (1) | EP3215529A1 (es) |
| JP (1) | JP2017533705A (es) |
| CN (1) | CN108064249A (es) |
| AR (1) | AR102417A1 (es) |
| CA (1) | CA2959551C (es) |
| MA (1) | MA40901A (es) |
| TW (1) | TWI585105B (es) |
| WO (1) | WO2016073406A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6592600B2 (ja) * | 2015-10-30 | 2019-10-16 | イーライ リリー アンド カンパニー | 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用 |
| TW201902926A (zh) * | 2017-05-03 | 2019-01-16 | 美商美國禮來大藥廠 | 抗cgrp／抗il-23雙特異性抗體及其用途 |
| AR112341A1 (es) | 2017-08-02 | 2019-10-16 | Lilly Co Eli | ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG |
| CN108640997A (zh) * | 2018-05-22 | 2018-10-12 | 蔡毓旻 | 一种双特异性抗体 |
| KR102088789B1 (ko) * | 2018-06-20 | 2020-03-13 | 인하대학교 산학협력단 | 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용 |
| TWI722535B (zh) | 2018-08-21 | 2021-03-21 | 美商美國禮來大藥廠 | 測定蛋白質或肽濃度的方法及其用途 |
| EP3972690A4 (en) * | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA |
| AU2020396204A1 (en) | 2019-12-06 | 2022-07-28 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting TNFα and IL-23 |
| WO2021228113A1 (zh) * | 2020-05-13 | 2021-11-18 | 信达生物制药(苏州)有限公司 | 包含抗IL-23p19抗体的制剂、其制备方法和用途 |
| WO2021234634A1 (en) * | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| CN112807428A (zh) * | 2020-06-12 | 2021-05-18 | 江苏荃信生物医药有限公司 | 包含抗人白介素23单克隆抗体的药物组合物 |
| TW202224702A (zh) * | 2020-09-10 | 2022-07-01 | 美商美國禮來大藥廠 | 治療性抗體調配物 |
| EP4261222A1 (en) * | 2020-12-09 | 2023-10-18 | HK inno.N Corporation | ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFalpha BISPECIFIC ANTIBODY, AND USES THEREOF |
| WO2024061288A1 (en) * | 2022-09-21 | 2024-03-28 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Antibodies targeting tnf alpha and il-23 and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| TR200503572T2 (tr) | 1999-03-25 | 2006-04-21 | Knoll Gmbh & Co. Kg. | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
| ES2637801T3 (es) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| CA2501786C (en) | 2002-10-30 | 2015-02-17 | Genentech, Inc. | Inhibition of il-17 production |
| ES2367302T3 (es) | 2002-12-23 | 2011-11-02 | Schering Corporation | Usos de la citoquina il-23 de mamífero; reactivos relacionados. |
| TWI357336B (en) | 2003-03-10 | 2012-02-01 | Schering Corp | Uses of il-23 agonists and antagonists; related re |
| TWI363091B (en) | 2004-12-20 | 2012-05-01 | Schering Corp | Uses of mammalian cytokine; related reagents |
| HUE042561T2 (hu) | 2005-06-30 | 2019-07-29 | Janssen Biotech Inc | Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2619052A1 (en) | 2005-08-25 | 2007-03-01 | Eli Lily And Company | Anti-il-23 antibiodies |
| EP3190125A1 (en) | 2005-08-31 | 2017-07-12 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
| ES2333260T3 (es) * | 2005-09-01 | 2010-02-18 | Schering Corporation | Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica. |
| DK3219328T3 (da) | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| JP2009540018A (ja) * | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| EP2097452A1 (en) * | 2006-12-14 | 2009-09-09 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
| EP2059534B1 (en) | 2007-02-23 | 2012-04-25 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| SG178804A1 (en) * | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
| JP5337055B2 (ja) * | 2007-02-28 | 2013-11-06 | メルク・シャープ・アンド・ドーム・コーポレーション | 免疫性障害の処置のための組合せ治療 |
| PT2274008E (pt) * | 2008-03-27 | 2014-05-12 | Zymogenetics Inc | Composições e métodos para inibição de pdgfrbeta e vegf-a |
| JP2011523853A (ja) | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリン及びその使用 |
| MX2011002159A (es) | 2008-08-27 | 2011-03-29 | Schering Corp | Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria. |
| JP2012507723A (ja) | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| US8722860B2 (en) * | 2009-04-16 | 2014-05-13 | Abbvie Biotherapeutics Inc. | Anti-TNF-α antibodies and their uses |
| WO2011017294A1 (en) * | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
| GB201013975D0 (en) * | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
| SG184473A1 (en) * | 2010-04-07 | 2012-11-29 | Abbvie Inc | Tnf-alpha binding proteins |
| CN103108886B (zh) | 2010-07-20 | 2016-08-24 | 赛法隆澳大利亚控股有限公司 | 抗il-23杂二聚体特异性抗体 |
| AR084210A1 (es) * | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| TWI671315B (zh) | 2011-03-28 | 2019-09-11 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| EP2771361A1 (en) | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Bispecific immunobinders directed against tnf and il-17 |
| US20140212425A1 (en) * | 2011-12-05 | 2014-07-31 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
| EP2855745A4 (en) * | 2012-06-01 | 2016-01-20 | Momenta Pharmaceuticals Inc | METHODS RELATING TO ADALIMUM AB |
| EP2935626A4 (en) | 2012-12-21 | 2016-07-20 | Merck Sharp & Dohme | BIOMARKER FOR RESPONSE TO A PSORIASIS TREATMENT |
| AR094877A1 (es) * | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
| TW201444867A (zh) | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體 |
| CA2906384A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
| EA039598B9 (ru) * | 2014-09-03 | 2022-03-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23а и фно-альфа, и его применение |
-
2015
- 2015-10-23 AR ARP150103442A patent/AR102417A1/es unknown
- 2015-10-26 TW TW104135138A patent/TWI585105B/zh not_active IP Right Cessation
- 2015-11-02 MA MA040901A patent/MA40901A/fr unknown
- 2015-11-03 EP EP15791228.8A patent/EP3215529A1/en not_active Withdrawn
- 2015-11-03 US US14/930,678 patent/US9718884B2/en not_active Expired - Fee Related
- 2015-11-03 CA CA2959551A patent/CA2959551C/en not_active Expired - Fee Related
- 2015-11-03 JP JP2017523213A patent/JP2017533705A/ja active Pending
- 2015-11-03 CN CN201580059953.8A patent/CN108064249A/zh active Pending
- 2015-11-03 WO PCT/US2015/058719 patent/WO2016073406A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN108064249A (zh) | 2018-05-22 |
| CA2959551A1 (en) | 2016-05-12 |
| JP2017533705A (ja) | 2017-11-16 |
| EP3215529A1 (en) | 2017-09-13 |
| TW201627321A (zh) | 2016-08-01 |
| US20160122429A1 (en) | 2016-05-05 |
| US9718884B2 (en) | 2017-08-01 |
| TWI585105B (zh) | 2017-06-01 |
| WO2016073406A1 (en) | 2016-05-12 |
| CA2959551C (en) | 2018-09-11 |
| MA40901A (fr) | 2017-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102417A1 (es) | Anticuerpos biespecíficos anti-tnf- / anti-il-23 | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| JP2022177090A5 (es) | ||
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| HRP20191470T1 (hr) | Heterodimerni proteini | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20200384A1 (es) | Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| AR112341A1 (es) | ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| HRP20181047T1 (hr) | Protutijela protiv kemokina pan-elr+ cxc | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |